NCT05733013招募中不适用
Outcomes of Patients With Thyroid Carcinoma Treated With Redifferentiating Agents as Part of Routine Clinical Care: A Prospective Data Collection Study
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Adverse events will be collected in every visit
研究概览
简要总结
The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≥ 18 years old at time of consent
- •Inclusion Criteria:
- •Patients diagnosed with RAI refractory thyroid cancer or unlikely to respond to RAI.
- •Patients who will receive redifferentiation agents prior to planned diagnostic and/or therapeutic use of radioactive iodine as part of routine clinical care.
- •Patients who have never received redifferentiation agents outside of a clinical trial or have received redifferentiation agents in the context of a clinical trial will be enrolled after the clinical team has decided to proceed with a redifferentiation agent as part of routine clinical care prior to diagnostic and/or therapeutic radioactive iodine administration.
- •Patients previously treated with redifferentiation agents as part of clinical care prior to diagnostic and/or therapeutic radioactive iodine administration who are willing to provide retrospectively collected data surrounding the time of the previous treatment and will provide prospective data from the time of consent.
排除标准
- •RAI refractory thyroid cancer patients that will receive redifferentiation agents prior to diagnostic and/or therapeutic use of radioactive iodine as part of a prospective clinical trial.
研究组 & 干预措施
Participants with refractory thyroid cancer patients
干预措施: Surveillance Visit (Other)
结局指标
主要结局
Adverse events will be collected in every visit
时间窗: 2 years
The primary objective of this protocol is to prospectively collect data on patients with radio-iodine refractory thyroid cancer or patients unlikely to respond to radioactive iodine prior, during and after initiation of redifferentiating agents used as part of routine clinical care with or without radioactive iodine treatment.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Thyroid Cancer in United Arab EmiratesThyroidCancerNCT04763122Tawam Hospital762
招募中
不适用
Improvements in Thyroid Tumor Surgery and the Prognosis, Diagnosis, Recurrence and Metastasis of PatientsLymph Node MetastasisPapillary Thyroid CancerCarcinogenesisNCT06468696Second Affiliated Hospital of Xi'an Jiaotong University170
已完成
3 期
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.Differentiated Thyroid CancerNCT00295763Genzyme, a Sanofi Company61
撤回
2 期
Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid CancerThyroidCancerNCT01396733Asan Medical Center
招募中
不适用
Focus on Values to Stimulate Shared DecisionsThyroid CancerNCT03905369Radboud University Medical Center128